Similar articles

• Development of HIV protease inhibitors: a survey.

  Ren S, Lien EJ. Ren S, et al. Prog Drug Res. 1998;51:1-31. Prog Drug Res. 1998. PMID: 9949858 Review.
• Prospective follow-up of 67 indinavir-experienced human immunodeficiency virus-infected and AIDS patients treated with the ritonavir/saquinavir combination.

  Lallemand F, Adda N, Schneider V, Jacomet C, Salhi Y, Rozenbaum W. Lallemand F, et al. Clin Infect Dis. 1999 May;28(5):1184-5. doi: 10.1086/517781. Clin Infect Dis. 1999. PMID: 10452672 No abstract available.
• Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

  Côté HC, Brumme ZL, Harrigan PR. Côté HC, et al. J Virol. 2001 Jan;75(2):589-94. doi: 10.1128/JVI.75.2.589-594.2001. J Virol. 2001. PMID: 11134271 Free PMC article.
• [HIV protease inhibitors].

  Rubio R, Romeu J, Viciana P, Redondo C. Rubio R, et al. Enferm Infecc Microbiol Clin. 1996 Oct;14 Suppl 1:10-4. Enferm Infecc Microbiol Clin. 1996. PMID: 9053020 Review. Spanish. No abstract available.
• [Clinical application of HIV protease inhibitors].

  Chiba N, Shintani M, Ueno T, Hayashi H. Chiba N, et al. Tanpakushitsu Kakusan Koso. 1998 May;43(6):744-51. Tanpakushitsu Kakusan Koso. 1998. PMID: 9612068 Review. Japanese. No abstract available.